NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Not Applicable

Terminated

• Conditions: Cancer of Lung; Neoplasms, Lung; Cancer of the Lung; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer; Non-Small-Cell Lung Carcinoma; Lung Cancer
• Interventions: Device: Microwave Ablation

• Registration Number: NCT03603652
• Lead Sponsor: Ethicon, Inc.

Brief Summary

Patients with medically inoperable primary soft tissue lesion of the lung will have transbronchial microwave ablation performed via transbronchial approach by an interventional pulmonologist or thoracic surgeon using CT imaging. Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging. Patients will be followed for one year following the ablation procedure for efficacy and safety.

Detailed Description

Patients with medically inoperable primary soft tissue lesion of the lung (lesions less than or equal to 2cm and located in the outer two-thirds of the lung and not closer than 1cm to the pleura) will have transbronchial microwave ablation performed using CT imaging. All ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.

Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging.

Patients will be followed for one year following the ablation procedure for efficacy and safety with specific follow-up visits at 30 days, 6 months, and 12 months post-ablation. A user experience questionnaire is completed by the treating physician to better understand the ease of the procedure.

Study Timeline

• Study First Submitted: 2018-05-16
• Study Start: 2018-06-29
• Study First Submitted QC: 2018-07-26
• Study First Posted: 2018-07-27
• Primary Completion: 2018-12-21
• Study Completion: 2019-10-24
• Results First Submitted: 2020-09-22
• Status Verified: 2020-12
• Results First Submitted QC: 2020-12-18
• Last Update Submitted: 2020-12-18
• Results First Posted: 2020-12-21
• Last Update Posted: 2020-12-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Signed informed consent.

2. Patients ≥ 18 years old.

3. Performance status 0-2 via ECOG (Eastern Cooperative Oncology Group) classification.

4. Willing to fulfill all follow-up visit requirements.

5. Medically inoperable primary soft tissue lesion of the lung or patient election not to have surgery. (Medically inoperable is defined per the following indicators: post op predictive FEV1 (forced expiratory volume in 1 second) < 40%; DLCO (diffusing capacity of the lung for carbon monoxide) < 40%; hypoxemia or hypercapnia diabetes with end-organ damage; or severe cerebral, cardiovascular, peripheral vascular disease, or chronic heart disease)

6. One soft tissue lesion ≤ 2 cm in the outer two thirds of the lung and not closer than 1 cm to the pleura.

   (Outer two thirds of the lung is defined as peripheral beyond the segmental airway, past the segmental bronchi, such that proximal endobronchial soft tissue lesions are avoided; soft tissue lesions should not be contiguous with the pleura)

7. Radiographic resolution of pneumonia

Exclusion Criteria

1. Scheduled concurrent procedure for the target soft tissue lesion other than those that are lung related.
2. Pregnant or breastfeeding.
3. Physical or psychological condition that would impair study participation.
4. Patients with uncorrectable coagulography at time of screening.
5. Patient with implantable devices, including pacemakers or other electronic implants.
6. Prior pneumonectomy or bronchiectasis.
7. Severe neuromuscular disease.
8. Platelet count ≤ 50,000/mm3.
9. ASA (American Society of Anesthesiologists) score of ≥ 4.
10. Inability to tolerate anesthesia.
11. Expected survival less than 6 months.
12. Clinically significant hypertension.
13. Chronic ventilator support, which uses bi-level positive airway pressure (PAP).
14. Endobronchial soft tissue lesions proximal to the segmental airways

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Microwave Ablation	Microwave Ablation	Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.

Primary Outcome Measures

Name	Time	Method
Number of Patients Whose Ablation Resulted in Technique Efficacy	30 days post-ablation	Ablation of the target lesion according to the protocol and covered completely, with an adequate margin, as defined by the performing physician (that is, the ablation zone completely overlaps or encompasses the target lesion plus an ablative margin), as assessed by CT imaging, 30 days (+/- 7 days) after the first ablation procedure.
User Experience Survey (Part II)	Immediately post-ablation	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked the time it took to place the probe in a position that was ready for ablation.
User Experience Survey (Part I)	Immediately post-ablation	A Sponsor-created survey completed by the treating physician immediately post-ablation. Questions were all YES/NO.
User Experience Survey (Part III)	Immediately post-ablation	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked how many cone-beam CT (CBCT) scans were taken to place the probe such that it was ready for ablation.
Number of Patients Whose Ablation Resulted in Technical Success	Immediately post-ablation (day 0)	Ablation of the target lesion according to the protocol and covered completely, with an adequate margin, as defined by the performing physician (that is, the ablation zone completely overlaps or encompasses the target lesion plus an ablative margin), as assessed by CBCT imaging, immediately following the procedure.
User Experience Survey (Part V)	Immediately post-ablation	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked how many times the probe had to be repositioned to complete the ablation procedure.
User Experience Survey (Part IV)	Immediately post-ablation	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked the distance of the tip of the probe to the center of the soft-tissue lesion (in mm) just before the ablation procedure was initiated.

Secondary Outcome Measures

Name	Time	Method
Number of Patients Who Experienced Target Lesion Recurrence	measured at 6 months and 1 year post-ablation	Analyzed at 6 months and 1 year post-ablation via CT imaging
Number of Patients Who Were Readmitted to the Hospital	Within 30 days post-ablation	Any readmission to the hospital within 30 days of the ablation procedure.

Trial Locations

Locations (5)

City of Hope; 🇺🇸 Duarte, California, United States

New York Presbyterian-Weill Cornell Medicine; 🇺🇸 New York, New York, United States

FirstHealth Moore Regional Hospital; 🇺🇸 Pinehurst, North Carolina, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States